PYXS

1.83

3.98% 0.07

Pre-mercato: 1.86 0.03 +1.64%

Pyxis Oncology Inc (PYXS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PYXS Giù? Forum Previsione

Precedente Chiudi:

$1.76

Aprire:

$1.88

Volume 24 ore:

1.10M

Relative Volume:

2.80

Capitalizzazione di mercato:

$115.03M

Reddito:

$13.86M

Utile/perdita netta:

$-79.62M

Rapporto P/E:

-1.4258

EPS:

-1.2835

Flusso di cassa netto:

$-63.51M

1 W Prestazione:

+7.65%

1M Prestazione:

+23.65%

6M Prestazione:

-53.20%

1 anno Prestazione:

+53.78%

Intervallo 1D:

$1.71

$1.955

Intervallo di 1 settimana:

$1.62

$1.955

Portata 52W:

$0.97

$5.55

Pyxis Oncology Inc Stock (PYXS) Company Profile

Nome

Pyxis Oncology Inc

Settore

Healthcare (1106)

Industria

Biotechnology (615)

Telefono

(617) 221-9059

Indirizzo

321 HARRISON AVENUE, BOSTON

Dipendente

Cinguettio

Prossima data di guadagno

2026-05-21

Ultimi documenti SEC

PYXS's Discussions on Twitter

Compare PYXS vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PYXS Pyxis Oncology Inc	1.83	115.03M	13.86M	-79.62M	-63.51M	-1.2835
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-03	Ripresa	Stifel	Buy
2025-09-04	Iniziato	Guggenheim	Buy
2024-11-21	Downgrade	William Blair	Outperform → Mkt Perform
2024-11-08	Iniziato	Stephens	Overweight
2024-08-08	Iniziato	Stifel	Buy
2024-05-07	Ripresa	Jefferies	Buy
2024-02-09	Iniziato	BTIG Research	Buy
2024-01-23	Iniziato	Leerink Partners	Outperform
2023-09-05	Iniziato	RBC Capital Mkts	Outperform
2021-11-02	Iniziato	BofA Securities	Neutral
2021-11-02	Iniziato	Credit Suisse	Outperform
2021-11-02	Iniziato	Jefferies	Buy

Mostra tutto

Pyxis Oncology Inc Borsa (PYXS) Ultime notizie

May 05, 2026

Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target - marketscreener.com

May 05, 2026

Wedbush initiated coverage on Pyxis Oncology with a new price target - Quantisnow

May 05, 2026

Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94 - MSN

May 05, 2026

May 01, 2026

Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7% - MarketBeat

May 01, 2026

Pyxis Oncology (PYXS) Management Strategy | Pyxis Oncology posts 15.6% EPS beat, no revenueInvestment Rating - Newser

May 01, 2026

Apr 30, 2026

Pyxis Oncology, Inc. Files Amended 8-K/A Report for 2026 with SEC – Company Details, Address, and Nasdaq Listing - Minichart

Apr 30, 2026

[ARS] Pyxis Oncology, Inc. SEC Filing - Stock Titan

Apr 30, 2026

Pyxis Oncology (NASDAQ: PYXS) details 2026 vote on directors and auditor - Stock Titan

Apr 30, 2026

Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS) - Stock Titan

Apr 30, 2026

Apr 29, 2026

PYXS Pyxis Oncology beats Q4 2025 loss estimates, but shares shed 2.35 percent amid weak investor reaction.EBIT Margin - Newser

Apr 29, 2026

Apr 28, 2026

Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus

Apr 28, 2026

Apr 27, 2026

PYXS Pyxis Oncology Q4 2025 narrower than expected per share loss sparks double digit share price jump today.Expert Stock Picks - Newser

Apr 27, 2026

Apr 25, 2026

Pyxis Oncology (PYXS) H.C. Wainwright 26th Annual Global Investment Conference summary - Quartr

Apr 25, 2026

Pyxis Oncology (PYXS) Proxy Filing Summary - Quartr

Apr 25, 2026

Pyxis Oncology (PYXS) Leerink Global Healthcare Conference 2025 Summary - Quartr

Apr 25, 2026

Apr 22, 2026

Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Apr 22, 2026

Apr 17, 2026

Pyxis presents preclinical data on MICVO in head and neck cancer - Investing.com Australia

Apr 17, 2026

Pyxis presents preclinical data on MICVO in head and neck cancer By Investing.com - Investing.com South Africa

Apr 17, 2026

Pyxis Oncology to Present New Preclinical Data Showing - GlobeNewswire

Apr 17, 2026

Apr 13, 2026

Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat

Apr 13, 2026

Apr 12, 2026

PYXS | Pyxis Oncology, Inc. Common Insider Trading - Quiver Quantitative

Apr 12, 2026

Growth Value: Will Pyxis Oncology Inc stock benefit from M ARate Cut & Weekly Stock Breakout Alerts - baoquankhu1.vn

Apr 12, 2026

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Apr 12, 2026

Apr 10, 2026

PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill

Apr 10, 2026

Apr 09, 2026

Stock Recap: Can Pyxis Oncology Inc benefit from deglobalization2026 Earnings & Verified Chart Pattern Signals - baoquankhu1.vn

Apr 09, 2026

Price Action: Is Pyxis Oncology Inc part of any major index2026 Reactions & Low Drawdown Momentum Ideas - baoquankhu1.vn

Apr 09, 2026

Apr 07, 2026

Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69%Fast Rising Picks - Newser

Apr 07, 2026

Apr 06, 2026

Trade Report: Can Pyxis Oncology Inc expand its profit marginsCPI Data & Safe Entry Momentum Stock Tips - baoquankhu1.vn

Apr 06, 2026

Is Pyxis Oncology (PYXS) Stock a Buy Now | Price at $1.45, Down 2.03%Continuation Signals - Newser

Apr 06, 2026

Apr 05, 2026

Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell - MarketBeat

Apr 05, 2026

Apr 04, 2026

PYXS Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 04, 2026

Mar 31, 2026

PYXS Earnings History & Surprises | EPS & Revenue Results | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill

Mar 31, 2026

Mar 30, 2026